Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer

Nuclear Medicine Communications

Volumn 34, Issue 2, 2013, Pages 155-161

  Havelund, Birgitte M ^a,b   Holdgaard, Paw C ^a   Rafaelsen, Søren R ^a   Mortensen, Lise S ^c   Theil, Jørn ^c   Bender, Dirk ^c   Pløen, John ^a   Spindler, Karen Lise G ^a,b   Jakobsen, Anders ^a,b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

18F fluoroazomycinarabinofuranoside; hypoxia; imaging; PET; radiotherapy; rectal neoplasm

Indexed keywords

CONTRAST MEDIUM; FLUOROAZOMYCINARABINOFURANOSIDE F 18; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER; CANCER SIZE; CELL HYPOXIA; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; FEASIBILITY STUDY; FEMALE; HUMAN; INTESTINE WALL; MALE; MUSCLE LEVEL; RADIOLOGICAL PARAMETERS; RECTUM CANCER; STANDARDIZED UPTAKE VALUE; TUMOR HYPOXIA;

AGED; BIOLOGICAL TRANSPORT; CELL HYPOXIA; FEASIBILITY STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECTAL NEOPLASMS; TUMOR BURDEN; URINARY BLADDER;

EID: 84871612265     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32835bd5bc     Document Type: Article

References (21)

1. Fleming FJ, Pahlman L, Monson JR. Neoadjuvant therapy in rectal cancer. Dis Colon Rectum 2011; 54:901-912.
2. Habr-Gama A, Perez RO, Nadalin W, Nahas SC, Ribeiro U Jr, Silva e Sousa AH Jr, et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg 2005; 9:90-99.
3. Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, et al.Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011; 29:4633-4640.
4. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38-47.
5. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26:638-648.
6. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005; 77:18-24.
7. Goethals L, Debucquoy A, Perneel C, Geboes K, Ectors N, De SH, et al. Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys 2006; 65:246-254.
8. Wendling P, Manz R, Thews G, Vaupel P. Heterogeneous oxygenation of rectal carcinomas in humans: a critical parameter for preoperative irradiation? Adv Exp Med Biol 1984; 180:293-300.
9. Sun X, Niu G, Chan N, Shen B, Chen X. Tumor hypoxia imaging. Mol Imaging Biol 2011; 13:399-410.
10. Busk M, Horsman MR, Jakobsen S, Hansen KV, Bussink J, van der Kogel A, et al. Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast? Radiother Oncol 2009; 92:429-436.
11. Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A, et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003; 30:317-326.
12. Postema EJ, McEwan AJ, Riauka TA, Kumar P, Richmond DA, Abrams DN, et al. Initial results of hypoxia imaging using 1-alpha-D-(5-deoxy-5-[18F]- fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging 2009; 36:1565-1573.
13. Souvatzoglou M, Grosu AL, Roper B, Krause BJ, Beck R, Reischl G, et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging 2007; 34:1566-1575.
14. Schuetz M, Schmid MP, Potter R, Kommata S, Georg D, Lukic D, et al. Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncol 2010; 49:941-947.
15. Garcia-Parra R, Wood D, Shah RB, Siddiqui J, Hussain H, Park H, et al. Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques. Eur J Nucl Med Mol Imaging 2011; 38:1816-1823.
16. Reischl G, Ehrlichmann W, Bieg C, Solbach C, Kumar P, Wiebe LI, et al. Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation. Appl Radiat Isot 2005; 62:897-901.
17. Roels S, Slagmolen P, Nuyts J, Lee JA, Loeckx D, Maes F, et al. Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG? Acta Oncol 2008; 47:1237-1248.
18. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008; 51:1641-1648.
19. Leisure GP, Vesselle HJ, Faulhaber PF, O'Donnell JK, Adler LP, Miraldi F. Technical improvements in fluorine-18-FDG PET imaging of the abdomen and pelvis. J Nucl Med Technol 1997; 25:115-119.
20. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69:541-551.
21. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005; 46:106-113.